Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) is anticipated to announce its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect Barinthus Biotherapeutics to post earnings of ($0.27) per share and revenue of $0.22 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 12:30 PM ET.
Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02. On average, analysts expect Barinthus Biotherapeutics to post ($0.93) EPS for the current fiscal year and ($1.07) EPS for the next fiscal year.
Barinthus Biotherapeutics Stock Performance
NASDAQ BRNS opened at $0.74 on Friday. The company has a fifty day simple moving average of $0.73 and a 200 day simple moving average of $0.66. The company has a market cap of $30.23 million, a P/E ratio of -0.72 and a beta of -0.37. Barinthus Biotherapeutics has a 1 year low of $0.51 and a 1 year high of $1.83.
Analyst Ratings Changes
Read Our Latest Research Report on Barinthus Biotherapeutics
Barinthus Biotherapeutics Company Profile
Barinthus Biotherapeutics plc is a clinical-stage biotechnology company developing T-cell immunotherapies designed to treat autoimmune diseases, chronic infections and cancer. The company’s approach is intended to direct or regulate immune responses with greater specificity, with the goal of restoring immune tolerance or strengthening disease-fighting T-cell activity.
Barinthus’ product pipeline includes VTP-1000, an investigational antigen-specific therapy being developed for celiac disease, and VTP-300, a therapeutic vaccine candidate aimed at chronic hepatitis B infection.
Featured Stories
- Five stocks we like better than Barinthus Biotherapeutics
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Barinthus Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barinthus Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
